Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829801 | 0.85 | HDAC1 (0.48) | HDAC1HDAC6GPR119KDM1ASCN5A | |
| SCHEMBL974103 | 0.82 | HDAC1 (0.44) | HDAC1HDAC6GPR119KDM1ASCN5A | |
| SCHEMBL1861484 | 0.81 | HSD11B1 (0.52) | HSD11B1HDAC1HDAC6MMP1BRD4 | |
| SCHEMBL31506836 | 0.80 | HSD11B1 (0.47) | HSD11B1GPR119KDM1AEGLN2BCHE | |
| SCHEMBL27809383 | 0.77 | HSD11B1 (0.54) | HSD11B1HDAC1HDAC6GPR119 | |
| SCHEMBL20639951 | 0.77 | GPR119 (0.49) | GPR119AREGLN2 | |
| SCHEMBL19280531 | 0.76 | HDAC1 (0.45) | HSD11B1HDAC1HDAC6GPR119KDM1A | |
| SCHEMBL973406 | 0.76 | KDM1A (0.43) | HSD11B1HDAC1HDAC6GPR119KDM1A | |
| SCHEMBL973416 | 0.74 | HSD11B1 (0.43) | HSD11B1HDAC1HDAC6GPR119KDM1A | |
| SCHEMBL21424895 | 0.74 | HDAC1 (0.57) | HDAC1HDAC6GPR119KDM1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4538270-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Sapiensbio Inc. (KR) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239227-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 사피엔스바이오 | 2023-12-14 | — | — | WO | disclosed |
| US-7947834-B2 | Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | HSD11B1, HSD3B1, ADH1C | HSD11B1 1/4885HDAC1 145/4885HDAC6 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.